MediciNova, Inc.
NASDAQ:MNOVBiotechnology
-$0.02 today
- Market cap
- $68.14M
- Beta
- 0.62
- P/E (TTM)
- -5.6
- EPS (TTM)
- -$0.24
Volume 0.12M
Average 0.04M
MNOV Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
MediciNova, Inc.NASDAQ: MNOV
Total Equity · Q1 FY2026 · quarter ended Mar 2026
Total equity falls 21.1% from a year ago
Total equity stood at $39.41M at the end of Q1 FY2026, down 21.1% from a year earlier and down 5.2% from the prior quarter. Over 3 fiscal years it compounded at -16.0% a year.
Context
- Total equity amounted to 92.3% of total assets at the end of Q1 FY2026, down 3.0 pp from a year earlier.
- Total equity increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total equity keeps falling in the next quarterly balance sheet after a -21.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 41.59M USD
- Year-over-year change
- -20.8%
- 4-year CAGR
- -16.0%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 41.59M | -20.8% |
| FY2024 | 2024-12-31 | 52.5M | -15.8% |
| FY2023 | 2023-12-31 | 62.38M | -11.2% |
| FY2022 | 2022-12-31 | 70.24M | -16.1% |
| FY2021 | 2021-12-31 | 83.68M | — |
Total Equity vs competitors
How MNOV compares with its peers on the latest reported figures
- MNOV's Mar 2026 total equity of $39.41M is the 9th highest of the 11 companies compared; the peer median is $96.22M.
- Its year-over-year change of -21.1% is the 5th highest of 11, against a peer median of -28.8%.
- Total equity amounts to 92.3% of total assets for MNOV, versus a peer median of 68.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $218.73M | +874.7% | -14.9% | 92.9% | |
| Mar 2026 | $202.37M | +523.0% | +7.5% | 56.7% | |
| Mar 2026 | $151.23M | +2960.5% | — | 79.7% | |
| Mar 2026 | $135.02M | -22.7% | -16.4% | 96.6% | |
| Mar 2026 | $96.92M | -53.9% | +7.4% | 48.0% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | Mar 2026 | $95.52M | -40.4% | -12.9% | 88.6% |
| Mar 2026 | $94.12M | +106.3% | -7.4% | 52.3% | |
| Mar 2026 | $87.97M | -45.1% | -24.8% | 91.1% | |
| Mar 2026 | $39.41M | -21.1% | -16.0% | 92.3% | |
CBUSCibus, Inc. | Mar 2026 | $35.48M | -52.0% | +44.5% | 10.9% |
| Mar 2026 | $18.72M | -34.9% | -35.2% | 40.4% | |
| Peer median (excluding MNOV) | $96.22M | -28.8% | -12.9% | 68.2% | |
Competitors are the stored peer set for MNOV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 71.43M | 18.51M | 51M | 40.36M | 30.81M |
| Short-term Investments | 0 | 39.98M | 0 | 0 | 0 |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 0 | 174.94K | 714.54K | 184.83K |
| Total Current Assets | 72.01M | 58.99M | 51.17M | 41.07M | 30.99M |
| Property, Plant & Equipment (Net) | 881.78K | 674.76K | 621.21K | 382.41K | 192.57K |
| Goodwill | 9.6M | 9.6M | 9.6M | 9.6M | 9.6M |
| Intangible Assets | 4.8M | 4.8M | 4.8M | 4.8M | 4.8M |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 115.49K | 92.79K | 74.15K | 19K | 19K |
| Total Non-current Assets | 15.4M | 15.17M | 15.1M | 14.8M | 14.61M |
| Total Assets | 87.41M | 74.15M | 66.27M | 55.88M | 45.6M |
| Account Payables | 402.74K | 424.65K | 1M | 1.1M | 625K |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 370.16K |
| Other Current Liabilities | 547.27K | 184.1K | 988.77K | 912.78K | 971.07K |
| Total Current Liabilities | 2.83M | 3.19M | 3.28M | 2.96M | 3.8M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 201.79K | 201.79K | 201.79K |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 201.79K | 201.79K | 410.66K | 211.46K | 17.13K |
| Total Non-current Liabilities | 896.47K | 725.41K | 612.45K | 413.25K | 218.92K |
| Total Liabilities | 3.73M | 3.91M | 3.89M | 3.37M | 4.02M |
| Common Stock | 49.04K | 49.05K | 49.05K | 49.05K | 49.22K |
| Retained Earnings | (393.06M) | (407.13M) | (415.7M) | (426.75M) | (438.75M) |
| Accumulated OCI | (98.88K) | (115.28K) | (118.09K) | (135.15K) | (127.18K) |
| Other Stockholders Equity | (0) | (1) | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 83.68M | 70.24M | 62.38M | 52.5M | 41.59M |
| Total Debt | 826.64K | 681.12K | 215.93K | 193.77K | 194.33K |
| Net Debt | (70.6M) | (17.82M) | (50.78M) | (40.17M) | (30.61M) |
MediciNova, Inc.
NASDAQ:MNOV
Intrinsic Alpha fair value
Locked
Current Price
$1.33
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.